SCHEMBL20134

SCHEMBL20134

c1cn2nc(Nc3ccc4nsnc4c3)nc2c(-c2cncs2)n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.36
EIF2AK4 Q9P2K8 1/20 0.36
JAK2 O60674 4/20 0.36
PTK2 Q05397 4/20 0.36
JAK3 P52333 3/20 0.36
CD38 P28907 9/20 0.34
IKBKB O14920 1/20 0.32
PTPN11 Q06124 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CG P48736 1/20 0.31
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30
PSENEN Q9NZ42 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21199 0.84 SYK (0.41) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL15218981 0.83 SYK (0.39) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL15207446 0.83 JAK2 (0.42) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL19949 0.82 CD38 (0.40) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL15208049 0.81 JAK2 (0.40) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL22305 0.81 SYK (0.41) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL20128 0.81 JAK2 (0.44) SYKJAK2PTK2JAK3PIK3CD
SCHEMBL21617 0.81 SYK (0.38) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL19081 0.80 SYK (0.35) SYKEIF2AK4JAK2PTK2JAK3
SCHEMBL19957 0.80 JAK2 (0.47) JAK2PTK2JAK3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609098-A1 TRIAZOLOPYRAZINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025186-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 SYK 1/4885EIF2AK4 1898/4885JAK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.